Company Profile

QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) is a specialty pharmaceutical company focused on the development and commercialisation of new treatments for pain management and abuse prevention products. The Company’s Dual Opioid® platform technology – a patented fixed-ratio combination of morphine and oxycodone – provides effective analgesia while decreasing the frequency and severity of clinically important opioid-related side effects. QRxPharma has three complementary pain management product formulations in late and early stage clinical development including: Moxduo® IR, an immediate release oral capsule for acute pain; Moxduo® CR, a controlled release oral tablet (with abuse deterrent and tamper resistant technologies) for chronic pain; and Moxduo® IV, an intravenous formulation for moderate to severe hospital-based pain.